EPSRC logo

Details of Grant 

EPSRC Reference: EP/N006399/1
Title: EHDA Network-Pharmaceutical EHDA Technology: Developing QbD Facilitated, Continuous and Scaled Therapy Enabling Platforms
Principal Investigator: Ahmad, Professor Z
Other Investigators:
Edirisinghe, Professor M
Researcher Co-Investigators:
Project Partners:
Ashland Composite Polymers BlueFrog Design Cardiff University
GEA Pharma Systems Ltd GenVolt Ltd GlaxoSmithKline plc (GSK)
Imperial College London Loughborough University OncoLytika
Rotronic Measurment Solution Sympatec UCL
Umetrics MKS AB University of Bath University of Birmingham
University of Nottingham University of Portsmouth University of Sheffield
University of Sunderland University of Surrey University of Sussex
Department: School of Pharmacy
Organisation: De Montfort University
Scheme: Network
Starts: 30 October 2015 Ends: 29 October 2017 Value (£): 169,320
EPSRC Research Topic Classifications:
EPSRC Industrial Sector Classifications:
Manufacturing Pharmaceuticals and Biotechnology
Related Grants:
Panel History:
Panel DatePanel NameOutcome
18 Jun 2015 Engineering Prioritisation Panel Meeting 18 June 2015 Announced
Summary on Grant Application Form
Advances in fit for use manufacturing of biopharmaceutical drug delivery and pharmaceutical systems are now required to fit Quality by Design (QbD) models. These current regulations require excellence to be built into the preparation of emerging products (both material and process) thereby leading to product robustness and quality. In addition, industrial needs (economical and reproducible quality enhancement) are driving manufacturing towards continuous processes over batch type processes which also rely on QbD (for integrity and quality). EHDA technology is a robust process that has been utilised in various formats (e.g. electrospinning, electrospraying, bubbling and even 3D printing) and is favourable due to applicability with the development of stable nanomedicines and biopharmaceuticals, the emergence of this technology is clearly evident in the UK and on the global scale. Attempts in scaling up (for suitable pharmaceutical scale) and in tandem with continuous processes (including controlled manufacturing) have been very limited. There also, now, remains a huge void in the adaptation of sensible QbD (multi-variate) for the current methods developed and also those required by industry. While lab scale research continues with the ongoing development of such processes (e.g. nanomedicines, smart and controlled delivery), the transition to industry or the clinic will have to meet these regulations (and scales) for there to be a real impact, which is now, also, an important aspect of grass root research in the UK.

The EHDA network brings together specialists from academia and industry to advance this technology through several means. Firstly, initiating developments towards a real-viable scale for Pharmaceutical production. Secondly, to incorporate developments in lean manufacturing and legislation (e.g. continuous manufacturing, online diagnostics, QbD and adaptable scale). Thirdly, to marry optimised lean technologies with novel and emerging macromolecular therapies and actives. The network has a wide range of activities and initiatives which will lead to significant developments (and collaborations) in an area of increasing global interest (EHDA processes) - but currently only on a viable lab scale to date. This network will be the first of its kind and will serve as the central and pioneering hub in this remit.
Key Findings
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Potential use in non-academic contexts
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Description This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Date Materialised
Sectors submitted by the Researcher
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Project URL:  
Further Information:  
Organisation Website: http://www.dmu.ac.uk